Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Diphtheria toxoid is an inactivated form of the diphtheria toxin, produced by *Corynebacterium diphtheriae*, and rendered non-toxic by formaldehyde treatment, preserving its immunogenicity[2][3][5]. It acts as an antigen in vaccines to elicit a protective antibody response without inducing disease. Tetanus toxoid is similarly an inactivated form of tetanus toxin (tetanospasmin), produced by *Clostridium tetani*, detoxified by heat and formaldehyde, and used in vaccines to induce immunity[7]. Both are essential components of combination vaccines used worldwide to prevent diphtheria and tetanus. These toxoids are not drug targets or receptors but are critical immunogens for vaccine-mediated prevention of bacterial infections. Their efficacy is monitored by measuring specific antibody titers, and they are considered to have an excellent safety profile with very rare serious adverse effects[7][5][2].
Induce humoral immunity via stimulation of neutralizing antibodies against native diphtheria toxin or tetanus toxin, conferring protection against disease upon exposure[7][5].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Diphtheria toxoid and Tetanus toxoid.